Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Context Therapeutics ( (CNTX) ) has issued an update.
Context Therapeutics announced the appointment of Andy Pasternak as Chairman of its Board of Directors following the resignation of Richard Berman. Pasternak, with extensive experience in the pharmaceutical industry, is expected to lead the company into its next phase of growth, leveraging his background to advance Context’s work in the evolving field of T cell engagers.
More about Context Therapeutics
Context Therapeutics Inc. is a biopharmaceutical company focused on advancing T cell engaging bispecific antibodies for solid tumors. The company is developing an innovative portfolio that includes therapeutics such as CTIM-76, CT-95, and CT-202. Context is headquartered in Philadelphia.
YTD Price Performance: -9.24%
Average Trading Volume: 532,980
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $81M
See more data about CNTX stock on TipRanks’ Stock Analysis page.
